Overview

Bioequivalence Study Between Two Albendazole 400 mg Tablets in Healthy Adult Participants Under Fed Conditions

Status:
COMPLETED
Trial end date:
2023-09-12
Target enrollment:
Participant gender:
Summary
The goal of this study is to compare two formulations of Albendazole of the same dose in healthy adult participants. Researchers will compare the extent and rate to which the drug is absorbed.
Phase:
PHASE1
Details
Lead Sponsor:
GlaxoSmithKline
Treatments:
Albendazole